Roche employees unite to raise funds for children in need
- Details
- Category: Roche
Today, Roche (SIX: RO, ROG; OTCQX: RHHBY) employees participate in the 2015 Roche Children's Walk at more than 131 company sites across the world. The funds raised through the event will be used to support children in need, either in the local community or in Malawi in Southeast Africa, one of the world's least developed countries.
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million
- Details
- Category: Bayer
Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation. The total consideration for the transaction is EUR 1,022 million (JPY 138 billion).
Patients reporting better quality of communication by their physician show improved self-care
- Details
- Category: Boehringer Ingelheim
New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed ('add-on'), is linked to future patient self-care and well-being.(1) Data from the IntroDia™ Survey have quantitatively demonstrated this link in the largest international survey of its kind, using responses from 4,235 people with T2D across 26 countries.*(1)
Get Ready. Get Set. Get Old.
- Details
- Category: Pfizer
Pfizer is challenging Americans to embrace aging as not an end, but a beginning - a time to fulfill old dreams and make new ones a reality. For graduation season 2015, "Get Ready. Get Set. Get Old." releases its "Commencement Day" video and new Get Old branding that serve as reminders of the inspiration, hopes and dreams that begin the next phase of every journey.
Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) today announced a collaboration with Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
- Details
- Category: Novartis
Novartis has announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar monotherapy alone.
AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly's VEGF Receptor 2 antiangiogenic cancer medicine.
More Pharma News ...
- Pfizer announces $3 million grants program to further clinical research in advanced breast cancer
- Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment
- AstraZeneca provides update on brodalumab development programme
- Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
- Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate
- AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden
- AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits